Disease · EFO_1001271
Atrophic Vaginitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Atrophic Vaginitis. Diseases, record EFO_1001271. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001271
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ESTRADIOL | CHEMBL135 | Small molecule | Approval | DailyMed | 16 | 13 | 13 | Drugs and targets |
| ESTROGENS, CONJUGATED | CHEMBL1201649 | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets | |
| DIENESTROL | CHEMBL1018 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| PRASTERONE | CHEMBL90593 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ESTRIOL | CHEMBL193482 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ESTROGEN | CHEMBL592868 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| ESTRADIOL VALERATE | CHEMBL1511 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MEGESTROL ACETATE | CHEMBL1201139 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXYTOCIN | CHEMBL395429 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| POLYCARBOPHIL | CHEMBL2108779 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ESR1 | Estrogen receptor | 5 | Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor modulator | Approval | https://conductscience.org/library/genes/2099 | Drugs and targets |
| ESR2 | Estrogen receptor | 2 | Estrogen receptor agonist; Estrogen receptor modulator | Approval | https://conductscience.org/library/genes/2100 | Drugs and targets |
| AR | Androgen receptor | 1 | Androgen Receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| OXTR | Oxytocin receptor | 1 | Oxytocin receptor agonist | Phase 2 | https://conductscience.org/library/genes/5021 | Drugs and targets |
| PGR | Progesterone receptor | 1 | Progesterone receptor agonist | Phase 3 | https://conductscience.org/library/genes/5241 | Drugs and targets |
Trials30
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03294538 | Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis | Phase 3 | 663 | 2019-12-26 | Atrophic Vaginitis | ESTRADIOL | Its record names the disease | ClinicalTrials.gov |
| NCT03332303 | Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy | Phase 3 | 540 | 2024-05-30 | Vulvar and Vaginal Atrophy | ESTRADIOL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02995694 | A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis | Phase 3 | 535 | 2021-12-01 | Atrophic Vaginitis | ESTRADIOL | Its record names the disease | ClinicalTrials.gov |
| NCT01256671 | DHEA Against Vaginal Atrophy - Safety Study of 12 Months | Phase 3 | 530 | 2017-10-18 | Vaginal Atrophy | PRASTERONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01358760 | Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy | Phase 3 | 450 | 2017-06-12 | Vaginal Atrophy | PRASTERONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02195986 | A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis | Phase 3 | 366 | 2017-09-06 | Atrophic Vaginitis | ESTRADIOL | Its record names the disease | ClinicalTrials.gov |
| NCT01256684 | DHEA Against Vaginal Atrophy - 3-Month Efficacy Study | Phase 3 | 255 | 2017-04-25 | Vaginal Atrophy | PRASTERONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01846442 | Topical DHEA Against Vaginal Atrophy | Phase 3 | 218 | 2017-04-28 | Vaginal Atrophy | PRASTERONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04574999 | Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy. | Phase 3 | 167 | 2020-12-11 | Vaginal Atrophy | ESTRIOL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00816556 | A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis | Phase 3 | 63 | 2014-03-28 | Atrophic Vaginitis | ESTRADIOL VALERATE, ESTRIOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 30
See all 30 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Generic Estradiol Vaginal Cream USP, 0.01% vs Estrace Vaginal Cream USP, 0.01%: Number of Participants Identified as Treatment Success After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups | 161 of 244 | 153 of 227 | 471 | NCT03294538 | Trial comparisons |
Generic Estradiol Vaginal Cream USP, 0.01% vs Estrace Vaginal Cream USP, 0.01%: Number of Participants Identified as a Responder After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups | 49 of 244 | 44 of 227 | 471 | NCT03294538 | Trial comparisons |
| Estradiol Vaginal Cream vs Estrace® 0.01% Cream: Primary Endpoint (Vaginal Cytology + Vaginal pH) Equivalence | 42 of 111 | 45 of 117 | 228 | NCT02195986 | Trial comparisons |
Estradiol Vaginal Cream vs Estrace® 0.01% Cream: Comparison of the Number of Participants With Treatment Success for the Patient Self-assessment of the Symptoms of Vulvar and Vaginal Atrophy - Equivalence | 72 of 97 | 63 of 91 | 188 | NCT02195986 | Trial comparisons |
| 0.005% Estriol Group vs Placebo Group: deaths from any cause | 0 of 114 | 0 of 53 | 167 | NCT04574999 | Trial comparisons |
| 0.005% Estriol Group vs Placebo Group: serious adverse events | 1 of 114 | 0 of 53 | 167 | NCT04574999 | Trial comparisons |
| 0.005% Estriol Vaginal Gel vs Placebo Vaginal Gel: deaths from any cause | 0 of 50 | 0 of 11 | 61 | NCT02413008 | Trial comparisons |
| 0.005% Estriol Vaginal Gel vs Placebo Vaginal Gel: serious adverse events | 1 of 50 | 0 of 11 | 61 | NCT02413008 | Trial comparisons |
| Estradiol Vaginal Insert vs No Treatment: deaths from any cause | 1 of 33 | 0 of 27 | 60 | NCT04079218 | Trial comparisons |
| Estradiol Vaginal Insert vs No Treatment: serious adverse events | 4 of 33 | 2 of 27 | 60 | NCT04079218 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials29
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001271
GET https://conductscience.org/api/diseases/v1/EFO_1001271/trials?page=2